FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: Association with disease stage and survival

Leukemia

Volumn 21, Issue 12, 2007, Pages 2512-2518

  Gjerdrum, L M ^a   Woetmann, A ^b   Odum, N ^b   Burton, C M ^a   Rossen, K ^c   Skovgaard, G L ^c   Ryder, L P ^a   Ralfkiaer, E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER INFILTRATION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL LABELING; CELL TRANSFORMATION; COMORBIDITY; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PLAQUE FORMING CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN BIOPSY; TUMOR CELL;

EID: 36348953150     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404913     Document Type: Article

References (41)

1. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31: 1122-1131.
2. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
3. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001; 27: 20-21.
4. Shevach EM. CD4+ CD25+ suppressor T cells: More questions than answers. Nat Rev Immunol 2002; 2: 389-400.
5. Shevach EM. Fatal attraction: Tumors beckon regulatory T cells. Nat Med 2004; 10: 900-901.
6. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
7. Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-1473.
8. Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G et al. High numbers of tumor infiltrating FOXP3-positive regulatory T-cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 2957-2964.
9. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N et al. Cutaneous T-cell lymphoma: Malignant proliferation of T-regulatory cells. Blood 2005; 105: 1640-1647.
10. Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N et al. Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20: 1123-1129.
11. Tiemessen MM, Mitchell TJ, Hendry L, Whittaker SJ, Taams LS, John S. Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages oi primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126 2217-2223.
12. Odum N, Hofmann B, Jakobsen B, Langhoff E, Morling N, Platz P et al. HLA-DP related suppression of mixed lymphocyte reaction with alloactivaied lymphocytes. Tissue Antigens 1986; 27: 32-43.
13. Woetmann A, Lovato P, Eriksen KW, krejsgaard T, Labuda T, Zhang Q et al. Non-malignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007; 109: 3325-3332.
14. Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen PB, Thestrup-Pedersen K. Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev. Biol 1992; 28A: 161-167.
15. Odum N, Bregenholt S, Eriksen KW, Skov S, Ryder LP, Bpndtzen K et al. The CC-chemokine receptor 5 (CCR5) is a marker of, but not essential fpr the development of human Th1 cells. Tissue Antigens 1999; 54: 572-577.
16. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW et al. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphomas. Leukemia 2006; 20: 1759-1766.
17. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma - an alternative method for HER-2/ neu analysis. J Mol Diagn 2004; 6: 42-51.
18. Ralfkiaer E, Willemze R, Meijer CJ, Dummer R, Jaffe ES, Swerdlow SH et al. Primary cutaneous peripheral T-cell lymphoma, unspecified. In: Leboit PE, Burg G, Weedon D, Sarasin A (eds). Pathology and Genetics of Skin Tumors. IARC Press: Lyon, France, 2006, pp 184-188.
19. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-4772.
20. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002; 168 4272-4276.
21. Chen ML, Pittet MJ, Gorelik L, Flavell RA, Weissleder R, von BH et al. Regulatory T cells suppress tumor-specific CD8T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-424.
22. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9: 606-612.
23. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98: 1089-1099.
24. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N et al. CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2006; 55: 1064-1071.
25. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949.
26. Wolf D, Rumpold H, Koppelstatter C, Gastl GA, Steurer M, Mayer G et al. Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother 2006; 55: 1198-1208.
27. Hirahara K, Liu L, Clark RA, Yamanaka K, Fuhlbrigge RC, Kupper TS. The majority of human peripheral blood CD4+CD25high-Foxp3+ regulatory T cells bear functional skin-homing receptors. J Immunol 2006; 177: 4488-4494.
28. Chong BF, Murphy JE, Kupper TS, Fuhlbrigge RC. E-selectin, thymus- and activation-regulated chemokine/CCL17, and inter-cellular adhesion molecule-1 are constitutively coexpressed in dermal microvessels: A foundation for a cutaneous immunosurveillance system. J Immunol 2004; 172: 1575-1581.
29. Kakinuma T, Sugaya M, Nakamura K, Kaneko F, Wakugawa M, Matsushima K et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: Serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48: 23-30.
30. Murakami M, Sakamoto A, Bender J, Kappler J, Marrack P. CD25+CD4+ T cells contribute to the control of memory CD8+ T cells. Proc Natl Acad Sci USA 2002; 99: 8832-8837.
31. Trzonkowski P, Szmit E, Mysliwska J, Dobyszuk A, Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004; 112: 258-267.
32. Miyara M, Sakaguchi S. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 2007; 13: 108-116.
33. Levings MK, Bacchetta R, Schulz U, Roncarolo MG. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263-276.
34. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res 2006; 66: 10145-10152.
35. Chen S, Ishii N, Ine S, Ikeda S, Fujimura T, Ndhlovu LC et al. Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells. Int Immunol 2006; 18: 269-277.
36. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol 2004; 126: 81-84.
37. Matsubara Y, Hori T, Morita R, Sakaguchi S, Uchiyama T. Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells. Leukemia 2005; 19: 482-483.
38. Roncador G, Garcia JF, Garcia JF, Maestre L, Lucas E, Menarguez J et al. FOXP3, a selective marker for a subset of adult T-cell leukaemia/ lymphoma. Leukemia 2005; 19: 2247-2253.
39. Walsh PT, Benoit BM, Wysocka M, Dalton NM, Turka LA, Rook AH. A role for regulatory T cells in cutaneous T-cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-ceil phenotype associated with HTLV-1 infection. J Invest Dermatol 2006; 126: 690-692.
40. Hallermann C, Niermann C, Schulze HJ. Regulatory T-cell phenotype in association with large cell transformation of mycosis fungoides. Eur J Haematol 2007; 78: 260-263.
41. Jaffe ES, Ralfkiaer E. Mature T-cell and NK-cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 189-235.